Mpox

Mpox is an exotic infectious disease caused by the Mpox virus. The disease was first identified in laboratory monkeys, thus earning its name, but in its natural state, it seems to infect rodents more than primates. A fever, headache, muscle pains, swollen lymph nodes, and fatigue are the first symptoms in humans. After this, a rash forms with blisters and crusts. Symptoms typically appear 7 to 14 days after exposure. In most cases, symptoms last 2 to 4 weeks. Children, pregnant women, and people with suppressed immune systems are at greater risk of severe cases.

Human Monkeypox – Epidemiology, Clinical Characteristics, Diagnosis, and Prevention

The human monkeypox virus, which belongs to the genus Orthopoxvirus of the family Poxviridae, is a DNA virus.

Monkeypox 2003 U.S. Outbreak

Monkeypox Epidemiology

Monkeypox; What is It and How Do We Treat It?

What is Monkeypox?

Latest Mpox News and Research

Weakened form of Mpox drove the 2022 global outbreak

The strain of Mpox behind the 2022 outbreak was a weakened form of the virus, which may have helped to spread it faster, a new study from the University of Surrey reports.

9 Sep 2026

Seminal fluid facilitates monkeypox virus entry into human cells

Monkeypox virus used to be transmitted predominantly from animals to humans. In recent years, however, new virus variants have become increasingly capable of spreading from person to person.

31 Aug 2026

Mathematical model shows combined strategies greatly reduce Mpox transmission

Mpox (formerly Monkeypox), a viral zoonotic disease, remains a global public health concern because it can spread between animals and humans and among people.

31 Aug 2026

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).

28 Aug 2026

New battery-powered device detects Bundibugyo Ebola virus in thirty minutes

Professor Yasutoshi Kido of the Graduate School of Medicine, Osaka Metropolitan University (OMU), in collaboration with K.K. DNAFORM and the National Institute for Biomedical Research (INRB) of the Democratic Republic of the Congo, is developing a portable rapid diagnostic system for Ebola virus disease (EVD) caused by Bundibugyo virus (BDBV).

17 Jul 2026

Fractional COVID booster doses provide strong long-lasting immunity

Smaller doses of COVID-19 booster vaccines can provide long-lasting immunity, helping to reduce costs and improve access to vaccination, according to new research. And the findings could also inform vaccine dosing and options during future pandemics.

16 Jul 2026

Machine learning boosts medicine access in resource-limited healthcare settings

Managing a medical supply chain in low- and middle-income countries can mean navigating a landscape prone to extreme and unexpected disruptions.

2 Jul 2026

New grants advance AI-powered wastewater pathogen surveillance

Detecting infectious disease threats early and responding quickly can dramatically alter the course of an infectious outbreak.

2 Jul 2026

Wastewater analysis offers novel approach to track HIV burden

Human immunodeficiency virus 1 (HIV-1) detection in wastewater offers a novel approach to monitor the virus in communities.

15 Jun 2026

Africa CDC and WHO unite to combat Ebola outbreak

The Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health Organization (WHO) today launched a joint continental preparedness and response plan on the ongoing Ebola outbreak caused by the Bundibugyo virus.

7 Jun 2026

Most Americans misunderstand which sexually transmitted infections have preventive vaccines

While data from the Centers for Disease Control and Prevention (CDC) show that the total number of U.S. cases of three sexually transmitted infections (STIs) declined from 2022-24, infection rates remain 13% higher than a decade ago. CDC provisional data show more than 2.2 million U.S. cases of chlamydia, gonorrhea, and syphilis were reported in 2024.

21 May 2026

Researchers track genetic changes in Brazil's rare Sabiá virus

The Sabiá virus causes an acute hemorrhagic and neurological syndrome. Four fatal cases have been recorded in the state of São Paulo since 1990.

20 May 2026

Asymptomatic transmission plays a prominent role in mpox infection patterns

A Kaiser Permanente study of nearly 8,000 men shows that in mid- to late 2024, mpox was far more common among men who have sex with men than previously thought. Individuals without symptoms accounted for most infections and likely played a prominent role in transmission, contrary to prior assumptions that people had to be symptomatic to spread the disease.

15 May 2026

New tools for quicker and easier Mpox diagnosis

Following the rise in monkeypox (Mpox) cases, particularly in countries where the disease had not traditionally been observed, the World Health Organization (WHO) declared a Public Health Emergency of International Concern in June 2022 and again in August 2024.

4 May 2026

ProImmune collaborates with The University of Texas Medical Branch to advance infectious disease research

ProImmune, Ltd., a global leader in immunological reagents and services, today announced a collaboration with The University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL), a high-containment, infectious disease research facility, to develop innovative tools for studying high-consequence emerging and endemic infectious diseases.

From ProImmune Ltd. 15 Apr 2026

WHO urges faster TB detection with new point-of-care tests

On World TB Day, the World Health Organization (WHO) is urging countries to accelerate action to end tuberculosis (TB) and expand access to lifesaving services by using new innovations such as diagnostic tests that can be used near the point-of-care and tongue swabs that can help detect the disease faster reaching more people.

24 Mar 2026